LONG BEACH, Calif. — In this video, Yasha S. M odi , MD , discusses end-of-study results for EYP-1901 from EyePoint Pharmaceuticals, a bioerodible, sustained-release intravitreal insert to deliver vorolanib for diabetic macular edema.

The phase 2 VERONA study met its primary endpoint, with more than 70% of participants who received high-dose EYP-1901 reaching 24 weeks before needing supplement injection.

“With that said, about one-third of patients still need repeat treatment,” Modi, of NYU Langone Health, told Healio at the American Society of Retina Specialists annual meeting. “So, we will have to follow these patients on a monthly basis in the clinical trial and will then have to devise a system to be able to ensure that they are getting supplements when they need them

See Full Page